GlassScriptPhysician profile
Mark Castellaw
NPI 1114928793
$4,532.46
in general payments reported to CMS, 2019-2025
28 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $232 · 2021: $69.17 · 2022: $1,270 · 2023: $978 · 2024: $551 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,524.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $377.71 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $331.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $279.57 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $268.76 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $237.09 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $230.42 | 2019-2025 | |
| Astellas Pharma US INC | $181.81 | 2019-2024 | Veozah |
| Abbvie INC. | $150.80 | 2019-2025 | Ubrelvy |
| Sanofi-Aventis U.S. LLC | $116.83 | 2019-2022 | |
| Amarin Pharma, INC. | $106.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $104.15 | 2022-2023 | Shingrix, Arexvy |
| Biohaven Pharmaceuticals, INC. | $86.59 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.83 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.32 | 2022-2024 | Glassia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.15 | 2020-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $71.82 | 2022 | |
| Janssen Pharmaceuticals, INC | $37.46 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $30.70 | 2022-2023 | Gvoke Hypopen |
| Seqirus USA INC | $29.70 | 2025 | Flucelvax, Fluad |
| Merck Sharp & Dohme LLC | $27.84 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Hologic Sales and Service, LLC | $17.63 | 2019 | |
| Genentech USA, INC. | $16.41 | 2019 | |
| Averitas Pharma INC. | $15.98 | 2023 | Qutenza |
| Currax Pharmaceuticals LLC | $15.93 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.09 | 2025 | Voquezna |
| Allergan, INC. | $13.55 | 2019 | |
| Nevro Corp. | $13.51 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Castellaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.